An Open-Label, Phase I Study to Evaluate the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors.

Trial Profile

An Open-Label, Phase I Study to Evaluate the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2013

At a glance

  • Drugs Eribulin (Primary) ; Ketoconazole
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 03 May 2011 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 03 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Nov 2010 Results reported at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top